Description

Motilal Oswal Multi Factor Passive Fund of Funds will be reopened for ongoing subscriptions, redemptions, and SIP/STP/SWP transactions on NSE MF Invest Platform from March 18, 2026.

Summary

NSE has informed its members that the Motilal Oswal Multi Factor Passive Fund of Funds (both Direct Growth and Regular Growth plans) will be reopened for ongoing subscriptions and redemptions, including SIP, STP, and SWP facilities, on the NSE MF Invest Platform effective March 18, 2026.

Key Points

  • Motilal Oswal Multi Factor Passive Fund of Funds reopens for ongoing transactions from March 18, 2026
  • Both Direct Growth (ISIN: INF247L01GT2) and Regular Growth (ISIN: INF247L01GU0) plans are available
  • Transactions supported: subscriptions, redemptions, SIP (Systematic Investment Plan), STP (Systematic Transfer Plan), and SWP (Systematic Withdrawal Plan)
  • Available on the NSE MF Invest Platform
  • Both plans are classified under the Equity category

Regulatory Changes

No regulatory changes. This is an operational update regarding the availability of an existing mutual fund scheme on the NSE MF Invest Platform.

Compliance Requirements

Members of NSE are notified to update their systems and inform clients accordingly about the availability of these schemes for ongoing transactions from the effective date.

Important Dates

  • March 18, 2026: Effective date for reopening of Motilal Oswal Multi Factor Passive Fund of Funds for ongoing subscriptions, redemptions, and SIP/STP/SWP on NSE MF Invest Platform

Impact Assessment

Limited market impact. This update enables investors to transact in the Motilal Oswal Multi Factor Passive Fund of Funds through the NSE MF Invest Platform, expanding access to this equity fund-of-funds product. The circular is informational for NSE members facilitating mutual fund transactions and has no broader market or regulatory implications.

Impact Justification

Routine mutual fund platform availability update for reopening of an existing fund for ongoing transactions; no regulatory changes or broad market impact.